A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
Condition: Recessive Dystrophic Epidermolysis Bullosa Intervention: Biological: FCX-007 (no generic name is established; see below for FCX-007 description) Sponsors: Fibrocell Technologies, Inc.; Castle Creek Pharmaceuticals, LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials